Updated results, published in Cancer, demonstrated that infigratinib retains significant activity in patients with metastatic urothelial cancer (mUC).
Moreover, the study found that the nature of mutations noted in upper tract urothelial carcinoma (UTUC) appears to differ from that of the mutations found in urothelial carcinoma of the bladder (UCB), with the caveat of a small sample size, a higher rate of FGFR3 S249C mutations, and a smaller repertoire of mutations observed.
Given the findings presented in this study regarding infigratinib in patients with UTUC, the researchers suggest the planning of a phase III, adjuvant study performed predominantly in this population.
“To our knowledge, these are the highest response rates achieved in a UTUC cohort to date and this is the only targeted therapy found to have differentiated efficacy in patients with UTUC compared with…
